Published in Science on December 18, 1992
Comprehensive Study of Post-surgical Pain After Pectus or Spine Surgery | NCT04031716
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A (2001) 7.15
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev (2009) 5.64
Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A (2002) 5.33
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol (2008) 5.32
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut (2004) 4.17
The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol (2000) 3.57
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A (1999) 3.54
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev (2008) 3.51
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol (2007) 3.16
Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci (2010) 3.11
Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol (2005) 2.98
Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci (2006) 2.81
CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol (2010) 2.74
Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A (2009) 2.68
Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther (2009) 2.55
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol (2002) 2.54
Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol (2009) 2.48
Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A (1995) 2.33
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A (1999) 2.31
Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci U S A (1997) 2.25
Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol (2009) 2.23
Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci U S A (2004) 2.23
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol (2001) 2.15
Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci U S A (1993) 2.10
Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol (2001) 2.07
Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J Physiol (2005) 2.06
Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J (2006) 2.01
Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol (2007) 2.01
Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry (2006) 2.01
Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A (2008) 1.97
Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest (1997) 1.95
The metabolic serine hydrolases and their functions in mammalian physiology and disease. Chem Rev (2011) 1.89
Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci U S A (2000) 1.89
2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A (2001) 1.86
Fatty acid amide hydrolase deficiency limits early pregnancy events. J Clin Invest (2006) 1.86
The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci U S A (1996) 1.84
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol (2006) 1.83
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol (2011) 1.81
The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol (2010) 1.79
Supply and demand for endocannabinoids. Trends Neurosci (2011) 1.78
Identification of intracellular carriers for the endocannabinoid anandamide. Proc Natl Acad Sci U S A (2009) 1.77
Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol (2006) 1.77
The endocannabinoid system: a general view and latest additions. Br J Pharmacol (2004) 1.77
Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci U S A (2003) 1.76
Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol (2005) 1.76
Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J (2000) 1.75
Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol (1996) 1.75
Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol (2008) 1.75
Cannabinoid pharmacology: the first 66 years. Br J Pharmacol (2006) 1.73
Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev (2003) 1.71
The endocannabinoid system in brain reward processes. Br J Pharmacol (2008) 1.71
Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem (2005) 1.71
Chemical probes of endocannabinoid metabolism. Pharmacol Rev (2013) 1.68
Label-free quantification of membrane-ligand interactions using backscattering interferometry. Nat Biotechnol (2011) 1.67
Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol (2001) 1.67
Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol (2003) 1.66
Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data. Psychopharmacology (Berl) (2003) 1.66
Pharmacology of traumatic brain injury: where is the "golden bullet"? Mol Med (2008) 1.63
Cannabinoids and neuroinflammation. Br J Pharmacol (2004) 1.62
The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci U S A (2005) 1.62
Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest (2003) 1.61
Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) (2003) 1.61
Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol (2005) 1.60
Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res (2011) 1.60
Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem (2008) 1.60
Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci (2012) 1.60
Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J (2013) 1.59
The endocannabinoid system and pain. CNS Neurol Disord Drug Targets (2009) 1.59
Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology (2007) 1.59
Cannabinoids as novel anti-inflammatory drugs. Future Med Chem (2009) 1.58
Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J (1997) 1.57
Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev (2011) 1.56
N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J (2000) 1.55
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol (2011) 1.53
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A (1998) 1.53
N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A (2006) 1.52
Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A (1999) 1.51
DAGLβ inhibition perturbs a lipid network involved in macrophage inflammatory responses. Nat Chem Biol (2012) 1.51
Cannabinoid CB1 receptor facilitation of substance P release in the rat spinal cord, measured as neurokinin 1 receptor internalization. Eur J Neurosci (2010) 1.50
A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci (2011) 1.50
Crystal Structure of the Human Cannabinoid Receptor CB1. Cell (2016) 1.50
The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol (2001) 1.49
Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J (2005) 1.48
A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc Biol Sci (1998) 1.48
Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue. Front Microbiol (2011) 1.46
Monoacylglycerol lipase limits the duration of endocannabinoid-mediated depolarization-induced suppression of excitation in autaptic hippocampal neurons. Mol Pharmacol (2009) 1.46
Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther (2008) 1.45
Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med (2009) 1.44
Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids. Prog Neuropsychopharmacol Biol Psychiatry (2009) 1.44
Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer (2012) 1.41
Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci U S A (2001) 1.41
Pot, heroin unlock new areas for neuroscience. Science (1992) 1.41
Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol (2002) 1.41
Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc Natl Acad Sci U S A (2008) 1.41
Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol (2002) 1.40
Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol (2002) 1.40
Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br J Pharmacol (1996) 1.40
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
Quantitative procedures for use with the Edman-Begg sequenator. Partial sequences of two unusual immunoglobulin light chains, Rzf and Sac. Biochemistry (1971) 6.10
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA (2001) 3.90
Preliminary experiments on the chemistry and pharmacology of cannabis. Nature (1970) 3.41
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature (2001) 3.33
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav (1991) 2.57
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol (1999) 2.56
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther (1994) 2.55
Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology (1980) 2.41
Inherited deficiency of the second component of complement. Rheumatic disease associations. J Clin Invest (1976) 2.38
A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol (1997) 2.35
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos (2003) 2.32
Effects of I.C.I. 50172 in man during erect exercise. Br Med J (1968) 2.22
Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol (2001) 2.22
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol (2001) 2.15
Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett (2000) 2.11
Marihuana chemistry. Science (1970) 2.10
The informative process in private medical consultations: a preliminary investigation. Soc Sci Med (1978) 2.03
Clinical significance of positive inotropic action of digoxin in patients with left ventricular disease. Br Heart J (1973) 2.02
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem (1997) 2.01
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (2000) 1.96
Motivations and perceptions of early adopters of personalized genomics: perspectives from research participants. Public Health Genomics (2011) 1.96
Chemical basis of hashish activity. Science (1970) 1.94
2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A (2001) 1.86
The ring test: a quantitative method for assessing the 'cataleptic' effect of cannabis in mice. Br J Pharmacol (1972) 1.86
Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol (2007) 1.85
An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol (1998) 1.83
The right ventricular infundibulum: has it a role? Eur J Echocardiogr (2003) 1.81
(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem (1994) 1.80
Early medical use of cannabis. Nature (1993) 1.80
Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 1.77
The 'rapid filling wave' of the apex cardiogram. Its relation to echocardiographic and cineangiographic measurements of ventricular filling. Br Heart J (1975) 1.75
Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol (1993) 1.73
Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J Biol Chem (1989) 1.72
Relation of isovolumic relaxation to left ventricular wall movement in man. Br Heart J (1979) 1.71
Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther (1999) 1.67
Hormonal regulation of protein degradation and synthesis in skeletal muscle. Fed Proc (1980) 1.65
Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol (1997) 1.61
Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res (2011) 1.60
Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J Neurosci (2001) 1.58
X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(d(pGpG))]. Science (1985) 1.57
Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism. Br J Pharmacol (1972) 1.56
Discovery and characterization of endogenous cannabinoids. Life Sci (1999) 1.56
Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend (2000) 1.55
Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol (2001) 1.54
The chronicity of symptoms and disability in Reiter's syndrome. An analysis of 131 consecutive patients. Ann Intern Med (1979) 1.53
Anandamide may mediate sleep induction. Nature (1997) 1.53
Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol (1997) 1.49
The use of beta-adrenergic receptor blocking drugs in dysrhythmias. Prog Cardiovasc Dis (1969) 1.47
AM630, a competitive cannabinoid receptor antagonist. Life Sci (1995) 1.46
The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc (1971) 1.44
Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem (1993) 1.44
Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol (1992) 1.44
Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J (2000) 1.44
Genetic polymorphism of mouse immunoglobulin light chains revealed by isoelectric focusing. J Exp Med (1976) 1.42
Biphasic effects of anandamide. Pharmacol Biochem Behav (1998) 1.41
Recent advances in the chemistry of hashish. Fortschr Chem Org Naturst (1967) 1.40
Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors. Br J Pharmacol (1999) 1.37
Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology (2001) 1.35
Results from a statewide approach to adolescent tobacco use prevention. Prev Med (1992) 1.34
Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia (2007) 1.33
Three decades of health care use by the elderly, 1965-1998. Health Aff (Millwood) (2001) 1.30
The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett (1967) 1.30
Self-reported sleep and mood disturbance in chronic pain patients. Clin J Pain (1998) 1.29
Continuous wave Doppler echocardiography and coarctation of the aorta: gradients and flow patterns in the assessment of severity. Br Heart J (1990) 1.27
Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol (1997) 1.26
Effect of type of haematology analyser on CD4 count. Lancet (1992) 1.26
Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis (1992) 1.23
Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol (2000) 1.23
Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia (2001) 1.22
Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee. Br J Cancer (1996) 1.22
Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity (2006) 1.22
A historical overview of chemical research on cannabinoids. Chem Phys Lipids (2000) 1.20
The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett (1995) 1.20
An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci (1995) 1.20
Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem (1993) 1.20
The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes. J Med Chem (1998) 1.20
Effects of delta9-tetrahydrocannabinol on the rates of oxygen consumption of mice. Br J Pharmacol (1977) 1.18